DGAP-News: Heidelberg Pharma Receives Milestone Payment from Partner Magenta for Dosing the First Patient with MGTA-117
Retrieved on:
Thursday, March 10, 2022
NASDAQ, Safety, Multiple myeloma, RNA transfection, Company, Frankfurt Stock Exchange, Antibody, ISIN, Achievement, Survival, ATACS, Eukaryote, Pharmacokinetics, CD37, Cancer, Non-Hodgkin lymphoma, ATAC, Lists of diseases, HPHA, Degenerative disease, Leadership, Patient, RNA polymerase II, Technology, Therapy, CSO, Control, FSE, Lymphatic system, RNA, PSMA, BCMA, Generic drug, Fine chemical, Vaccine, Heidelberg Pharma's proprietary ATAC(R) technology, Heidelberg Pharma, Magenta Therapeutics, HEIDELBERG PHARMA'S PROPRIETARY ATAC(R) TECHNOLOGY, HEIDELBERG PHARMA, MAGENTA THERAPEUTICS
Ladenburg, Germany, 10 March 2022 - Heidelberg Pharma AG (FSE: HPHA) today announced that its cooperation partner Magenta Therapeutics, Cambridge, MA, USA, (Magenta; NASDAQ: MGTA) has dosed the first patient with the development candidate MGTA-117 in a Phase I/II study.
Key Points:
- Ladenburg, Germany, 10 March 2022 - Heidelberg Pharma AG (FSE: HPHA) today announced that its cooperation partner Magenta Therapeutics, Cambridge, MA, USA, (Magenta; NASDAQ: MGTA) has dosed the first patient with the development candidate MGTA-117 in a Phase I/II study.
- The achievement of this milestone triggered a milestone payment to Heidelberg Pharma.
- MGTA-117 is an Antibody Amanitin Conjugate based on Heidelberg Pharma's proprietary ATAC(R) technology and developed by Magenta.
- Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies.